Company Overview and News

 
Reappointment as MD: Apollo board to seek neutral view on Kanwar compensation

2018-10-03 financialexpress
Forced by minority shareholders to reconsider the re-appointment of Neeraj Kanwar as managing director, Apollo Tyres said on Wednesday the board would back the re-appointment while seeking an independent assessment on the compensation. Minority shareholders had defeated a special resolution to extend Kanwar’s tenure beyond 2019, ostensibly unhappy with the very high compensation package, estimated by proxy advisory firm IIAS at around Rs 65 crore.
GOODYEAR 500877 500168 APOLLOTYRE AYRQY

 
Evaluating entering various tyre segments in India: Goodyear

2018-07-13 moneycontrol
Tyre maker Goodyear India is evaluating to enter various segments, including commercial vehicles tyres, as part of plans to expand operations in the country, a top company official said today.
GOODYEAR 500168

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to NSE:GOODYEAR / GOODYEAR INDIA LTD. on message board site Silicon Investor.

Goodyear Tire u0026 Rubber GT Goodyear Tire u0026 Rubber GT Goodyear Tire u0026 Rubber GT GT: Goodyear Tire u0026 Rubber GT: Goodyear Tire u0026 Rubber GT: Goodyear Tire u0026 Rubber
GT: Goodyear Tire u0026 Rubber GT: Goodyear Tire u0026 Rubber GT: Goodyear Tire u0026 Rubber Goodyear Tire u0026 Rubber (NYSE:GT) Goodyear Tire u0026 Rubber (NYSE:GT) Goodyear Tire u0026 Rubber (NYSE:GT)